Lisata Therapeutics' CEO Dr. David Mazzo and CMO Dr. Kristen Buck On the Promise Of Certepetide for Pancreatic Cancer episode artwork

EPISODE · Jul 18, 2025 · 23 MIN

Lisata Therapeutics' CEO Dr. David Mazzo and CMO Dr. Kristen Buck On the Promise Of Certepetide for Pancreatic Cancer

from WTR Small-Cap Spotlight

Send us Fan MailIn this episode of WTR Small-Cap x Healthcare Spotlight crossover episode, we are joined by Lisata Therapeutics' (NASDAQ: LSTA) CEO David Mazzo, PhD and Chief Medical Officer Kristen Buck, MD to talk about, Certepetide, the company's novel solid tumor targeting and penetration technology with tumor microenvironment modifying properties.  We also dive into the recently reported positive preliminary results from Lisata's lead program (Ascend), a Phase 2b study investigating Certepetide for metastatic pancreatic ductal adenocarcinoma (the most common and aggressive form of pancreatic cancer), Lisata's partnerships, and upcoming milestones.  

Episode metadata supplied by the publisher feed · Published Jul 18, 2025

Embed this episode

Ready to play

Lisata Therapeutics' CEO Dr. David Mazzo and CMO Dr. Kristen Buck On the Promise Of Certepetide for Pancreatic Cancer

0:00 23:27

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of WTR Small-Cap Spotlight?

This episode is 23 minutes long.

When was this WTR Small-Cap Spotlight episode published?

This episode was published on July 18, 2025.

Can I download this WTR Small-Cap Spotlight episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!